Introduction
============

Lung cancer is the most frequently occurring cancer and the leading cause of cancer-associated mortality in China ([@b1-ol-0-0-9906]). Lung cancer involves malignant proliferation, invasion and metastasis ([@b2-ol-0-0-9906]). Surgery is a possible cure for early stage lung cancer ([@b3-ol-0-0-9906]); however, the majority of tumors are already in advanced stages when discovered ([@b4-ol-0-0-9906],[@b5-ol-0-0-9906]). Despite the emergence of new treatments, including targeted therapies and immunotherapy, certain patients with advanced or recurrent lung cancer require systemic chemotherapy ([@b6-ol-0-0-9906]). However, systemic chemotherapy commonly results in side effects including nausea, vomiting and diarrhea ([@b7-ol-0-0-9906],[@b8-ol-0-0-9906]). These side effects may worsen the patient\'s nutritional status, reduce immune function, delay the treatment cycle and increase the treatment costs ([@b9-ol-0-0-9906]--[@b11-ol-0-0-9906]). Among these effects, chemotherapy-induced diarrhea may be caused by intestinal epithelial cell apoptosis, intestinal barrier dysfunction, alterations to the intestinal flora and proinflammatory cytokine production ([@b12-ol-0-0-9906]).

Studies on intestinal flora have identified certain bacteria that are beneficial to the body, which when ingested in sufficient quantities can exhibit a positive effect on the host and serve as a probiotic ([@b13-ol-0-0-9906]). Probiotics may help to repair the intestinal barrier, alleviate gastrointestinal inflammation and maintain gut homeostasis; more specifically, *Clostridium butyricum (C. butyricum)* has been reported to regulate the gut homeostasis, reduce inflammation and reduce the incidence of diarrhea in digestive diseases including inflammatory bowel disease (IBD) ([@b14-ol-0-0-9906],[@b15-ol-0-0-9906]), and has been used to treat gastrointestinal disorders, including IBD and antibiotic-associated diarrhea ([@b16-ol-0-0-9906],[@b17-ol-0-0-9906]).

Therefore, it is speculated that the use of probiotics, including *C. butyricum*, may reduce chemotherapy-induced diarrhea (CID). However, there is currently not sufficient and clear clinical evidence to support the safety and efficacy of any probiotics, including the use of *C. butyricum* in CID ([@b18-ol-0-0-9906],[@b19-ol-0-0-9906]). The present study adopted the design of a prospective clinical trial to study the role of *C. butyricum* in patients with lung cancer undergoing chemotherapy. In this trial, blood samples were collected and analyzed to evaluate inflammatory, immune and nutritional indicators. The fetal flora were analyzed using the 16S ribosomal RNA (rRNA) sequencing technique, and the association between probiotic use, the inflammatory response, immunity and nutrition was investigated, to provide supporting evidence for the use of probiotics in clinical practice.

Materials and methods
=====================

### Patients

Patients with lung cancer who were admitted to the Shandong Provincial Hospital (Jinan, China) for chemotherapy were recruited between July 2015 and June 2016. The inclusion criteria were as follows: i) Between 18 and 80 years old; ii) diagnosed with lung cancer as the first primary tumor. The exclusion criteria were as follows: i) Severe systemic diseases including heart, liver or kidney dysfunction; ii) previous chemotherapy or other anti-cancer therapies; iii) probiotic, prebiotic or antibiotic therapy during the 2 months prior to recruitment; iv) allergy to micro ecological agents; v) pregnant or breast feeding women; vi) coagulopathy; and vii) the inability to provide informed consent. All participants provided written informed consent. The protocol was approved by the Institutional Ethics Committee of Shandong Provincial Hospital and registered at [ClinicalTrials.gov](ClinicalTrials.gov) with the identifier NCT02771470. The registration date was June 14th, 2015. The procedures were conducted in accordance with the approved guidelines.

### Study design

The present study was prospective, random, double blind and placebo comparative; the work flow is illustrated in [Fig. 1](#f1-ol-0-0-9906){ref-type="fig"}. A total of 50 patients were recruited and assessed for eligibility. Five patients were excluded as they did not meet the inclusion criteria (n=1), met the exclusion criteria (n=2) or for another reason (n=2). And then forty-five patients were randomly placed at a 1:1 ratio in the *C. butyricum* group (CB) or the placebo group using a random number table (n=23 in CB group, n=22 in placebo group). Ultimately, 41 patients were included in the final cohort. Patients were subjected to platinum-based combination chemotherapy every 3 weeks according to the National Comprehensive Cancer Network guidelines ([@b20-ol-0-0-9906]). Patients were administered treatment at two time points; the day preceding the first course of chemotherapy (baseline) and the day preceding the second course (week three). From the baseline day, three *C. butyricum* (420 mg/tablet) or placebo tablets (Qingdao East China Sea Pharmaceutical Co., Ltd, Qingdao, China) were administered three times per day, for 3 weeks. The treatments were administered by assistants who were not aware of whether the drugs were placebo or not. Blood and stool samples were collected at the two time points.

### Record of adverse effects

Adverse effects, including nausea, vomiting and diarrhea were assessed and graded according to the Criteria for Adverse Events, version 4 ([@b21-ol-0-0-9906]). Nausea is a disorder characterized by a queasy sensation and/or the urge to vomit. The grade of nausea was divided into three levels as follows: i) Loss of appetite without alteration in eating habits; ii) decreased oral intake without significant weight loss, dehydration or malnutrition; or iii) inadequate oral caloric food or fluid intake, tube feeding, total parenteral nutrition, or hospitalization indicated. Vomiting is a disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth. The grade of vomiting was divided into five levels as follow: i) One to two episodes within 24 h; ii) three to five episodes within 24 h; iii) more than six episodes within 24 h, tube feeding, total parenteral nutrition or hospitalization indicated; iv) life-threatening consequences, urgent intervention indicated; or v) mortality. Diarrhea is a disorder characterized by frequent and watery bowel movements, and the grade of diarrhea was divided into five levels as follows: i) An increase in stool evacuation per day of less than four times above baseline; ii) an increase in stool evacuation per day of four to six times above baseline; iii) an increase in stool evacuation per day of more than seven times above baseline, incontinence and hospitalization indicated; iv) life-threatening consequences, urgent intervention indicated; or v) mortality. The grade scores were evaluated and recorded.

### Blood testing

Morning fasting venous blood was taken for routine blood testing with the XN-9000 automatic hematology analyzer (Sysmex Corporation, Kobe, Japan) and albumin evaluation with the Olympus AU5800 biochemical analyzer (Beckman Coulter, Inc., Brea, CA, USA).

Lymphocyte subsets including CD4^+^ T lymphocytes, CD8^+^ T lymphocytes, natural killer (NK) cells and CD19^+^ B lymphocytes were quantified by flow cytometry. First, 2 ml of fasting blood was extracted and placed in EDTA-K2 anticoagulant tube, where it was mixed well and stored at room temperature (25°C) for \<24 h. A 12×75 mm Falcon tube was then marked with the sample number. Each blood sample was added to two tubes containing two different types of mixed antibody reagents included in the BD MultiTEST IMK kit (catalog no. 340505; Becton, Dickinson and Company, Franklin Lakes, NJ, USA). One was the BD Multitest CD3/CD8/CD45/CD4 mixed antibody reagent, including the following antibodies: Anti-CD3-FITC, anti-CD8-PE, anti-CD45-PerCP and anti-CD4-APC. The other reagent was the BD Multitest CD3/CD16CD56/CD45/CD19 mixed antibody reagent, including the following antibodies: Anti-CD3-FITC, anti-CD16/56-PE, anti-CD45-PerCP and anti-CD19-APC. Each mixed antibody reagent contained 20 µl and was provided in 1 ml of buffered saline with 0.1% sodium azide. Subsequently, 50 µl of each blood sample was added to the bottom of the sample tubes. The antibody was then mixed with the blood sample at low speed for 3 sec and incubated at room temperature for 15 min in the dark. Following the incubation, 450 µl of 1 × FACS hemolysin (Becton, Dickinson and Company) was added to each tube. The sample mixed with antibody reagent 1 was incubated at room temperature for 15 min in the dark. Simultaneously, the sample mixed with antibody reagent 2 was incubated at room temperature for 10 min in the dark. The samples were then measured using a flow cytometer and analyzed automatically by FACS Canto Clinical software version 2.4 (FACS Canto II; Becton, Dickinson and Company). Samples positive for CD4-APC, CD3-FITC and CD45-PerCP were classified as CD4+ T lymphocytes. Samples positive for CD8-PE, CD3-FITC and CD45-PerCP positive were CD8+ T lymphocytes. Samples positive for CD16/56-PE, CD3-FITC and CD45-PerCP positive are NK cells. CD19-APC, CD3-FITC and CD45-PerCP were determine to be B lymphocytes.

Immunoglobulins (Igs) were measured by the scattering turbidimetric method ([@b22-ol-0-0-9906]) using the Siemens BNII specific protein analyzer (Siemens AG, Munich, Germany). The following inflammatory response biomarker ratios were evaluated: Neutrophil lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR) and platelet/lymphocyte ratio (PLR).

Stool specimens test methods
----------------------------

### DNA extraction and sequencing

Stool samples (\~2--4 g) were placed into sterile tubes, and frozen at −20°C within 5 min, and subsequently stored at −80°C within 24 h. The total DNA was extracted, amplified and sequenced by Shanghai Majorbio Pharmaceutical Technology Co., Ltd. (Shanghai, China) according to the standardized protocol 19. The V3-V4 region of the 16S ribosomal subunit gene was amplified using 338F/806R barcoded primers (338F, 5′-ACTCCTACGGGAGGCAGCAG-3′ and 806R, 5′-GGACTACHVGGGTWTCTAAT-3′) and sequenced using the Illumina Miseq PE300 platform (Shanghai Majorbio Pharmaceutical Technology Co., Ltd.).

### Raw sequencing data processing

Sequencing data was obtained using Mothur Software v 1.33.0 (<https://www.mothur.org/>). The raw sff files were decoded, denoised, trimmed and aligned to Silva references (Release 119) ([@b23-ol-0-0-9906]) using the default parameters. The sequences were clustered with the same operational taxonomy unit (OTU) if their distances were \<0.03. Taxonomy was assigned to each OTU using the classify.otu command and further represented by the finest taxonomic name. The OTU table was converted to biom files, and the taxa relative abundances at domain to genus levels were generated using the summarize_taxa.py command in QIIME v1.8.0 (<http://qiime.org/>).

### Community diversity analysis and significance test for quantity differences evaluation

The community diversity was evaluated prior to conducting the significant test for quantity difference evaluation between groups, using the Illumina Miseq PE300 platform (Shanghai Majorbio Pharmaceutical Technology Co., Ltd, Shanghai, China). The Shannon index and Chao index were calculated to indicate community diversity and richness. Principal coordinates analysis (PCoA) is a visualization method to evaluate the similarity or variability of data. Analysis of similarities (ANOSIM) serves to test whether differences between groups are significantly greater than intra-group differences to determine whether grouping makes sense. Adonis analysis analyzes the different grouping factors to explain the differences between samples. Species diversity was tested in different microbial community groups to assess the significance of the observed differences based on the obtained community abundance data.

### Statistical analysis

The Wilcoxon test was used to compare the difference of each index and the difference of changes of each index of two groups using R 3.4.3 (<https://www.r-project.org/>). The Kruskal-Wallis test with Dunn multiple comparisons test was used to analyze the difference of OTUs between two groups. Community diversity analysis and significant differences were analyzed using the Illumina Miseq PE300 platform. Results are expressed as mean ± standard deviation of at least ten independent experiments. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics and adverse events

The characteristics of the patients are displayed in [Table I](#tI-ol-0-0-9906){ref-type="table"}. No significant difference was observed regarding age, gender or tumor stage between the two groups, and no *C. butyricum* infection was observed following administration of the interventional drug. The difference in body weight, grade of gastrointestinal reaction, hematological indicators and intestinal flora composition were compared between the two groups. At baseline no difference was observed between the two groups regarding weight ([Table II](#tII-ol-0-0-9906){ref-type="table"}). At week 3, a slight weight decrease was observed in the two groups, but the difference was not significant. The severity of nausea and vomiting was lower in the CB group compared with the placebo group. The incidence of diarrhea in the CB group was significantly lower compared with the placebo group ([Table III](#tIII-ol-0-0-9906){ref-type="table"}). These results suggested that administration of *C. butyricum* was safe and may reduce the incidence of chemotherapy-induced diarrhea, with little effect on patient weight.

### Blood test index

The effects of *C. butyricum* on the inflammatory response, immune function and nutritional status were evaluated by analyzing the differences between the two groups regarding blood cell count, systemic inflammatory response (SIR) biomarkers, lymphocyte subsets, immunoglobulin and albumin. The change in blood cell count and SIR biomarkers LMR, NLR and PLR was compared ([Fig. 2](#f2-ol-0-0-9906){ref-type="fig"}). At baseline, the blood cell count and SIR biomarkers revealed no significant difference between the two groups. At week 3, the number of lymphocytes increased in the CB group and decreased in the placebo group, and the change between the two groups was significantly different (P\<0.05). PLR decreased in the two groups, but a significant difference was only observed for the CB group. In addition, a significant difference was revealed between the two groups (P\<0.05). NLR decreased in the two groups, but only demonstrated a significant decrease in the CB group (P\<0.05). LMR increased in the CB group and decreased in the placebo group, though the difference was not significant. However, at week 3, LMR was significantly higher in the CB group compared with the placebo group (P\<0.05). Subsequently, the peripheral blood lymphocyte subsets representing the cellular immune system were analyzed ([Table IV](#tIV-ol-0-0-9906){ref-type="table"}). Cluster of differentiation (CD)16^+^CD56^+^ designation represented the natural killer (NK) cells, and CD19^+^designation represented the B lymphocyte population. The results revealed that the levels of CD3^+^CD8^+^ and CD16^+^CD56^+^ in the CB group were higher compared with the placebo group, though the difference was not significant. CD3^+^CD4^+^ percentage and ratio in the CB group displayed a decreasing trend. However, no significant difference was observed in the changes of these indicators between the two groups. Humoral immune function was also investigated by evaluating IgG, IgA, IgM and IgE levels ([Table V](#tV-ol-0-0-9906){ref-type="table"}). The results revealed that all of these immunoglobulins decreased in the two groups, although without any significant difference. Alterations in albumin expression levels were also evaluated ([Table II](#tII-ol-0-0-9906){ref-type="table"}). Albumin expression increased in the CB group and decreased in the placebo group, although the difference was not significant. Overall, through blood indicator analysis, it was established that the SIR index in the CB group was significantly improved compared with the placebo group, suggesting that *C. butyricum* reduces the systemic inflammatory response. However, lymphocyte subsets, immunoglobulin and albumin expression levels did not significantly alter.

### Fecal flora analysis

16S rRNA pyrosequencing was used to analyze variations in fecal flora to evaluate the effects of *C. butyricum* on intestinal flora. A total of 2,990,797 reads were analyzed following sequence denoising, trimming and chimera picking. The average sequence length was 435.52 bps. A total of 673 OTUs were clustered by 97% similarity. The sequencing depth was assessed by plotting the rarefaction curve for each sample ([Fig. 3](#f3-ol-0-0-9906){ref-type="fig"}). The majority of the samples reached their plateaus, confirming the adequacy of sequencing. The microbial alpha-diversity between the CB and placebo groups was compared using the Shannon and Chao indexes ([Fig. 4](#f4-ol-0-0-9906){ref-type="fig"}). The difference in diversity between the CB and the placebo groups were compared at and between the two time points selected. The results indicated that the Shannon and Chao indexes increased in the CB group, yet decreased in the placebo group, although without any indication of significance. β-diversity was subsequently compared by PCoA analysis. The analysis of OTU levels suggested that the factors explaining the differences in the data were small at baseline or week 3 ([Fig. 5](#f5-ol-0-0-9906){ref-type="fig"}). Adonis and ANOSIM analysis were performed, which indicated that grouping did not make sense at baseline or week 3 ([Tables VI](#tVI-ol-0-0-9906){ref-type="table"} and [VII](#tVII-ol-0-0-9906){ref-type="table"}). These results suggested a minimal difference between the two groups at baseline or week 3. Variation at the phylum ([Fig. 6](#f6-ol-0-0-9906){ref-type="fig"}) and genus ([Fig. 7](#f7-ol-0-0-9906){ref-type="fig"}) levels were calculated in the two groups. The flora were divided into four phyla: *Firmicutes, Bacteroidetes, Proteobacteria* and *Actinobacteria*. The proportion of each phylum in the CB group was marginally altered after 3 weeks, whilst the proportion of *Firmicutes* decreased significantly in the placebo group (P\<0.05). In regard to the genus level, no significant difference was observed in either group, but specific trends were observed. Beneficial genera including *Lactobacillus*, and the majority of genera producing short-chain fatty acids, including *Faecalibacterium, Clostridium, Blautia* and *Roseburia*, were elevated in the CB group, while the pathogenic bacteria *Escherichia-Shigella* were decreased. These trends were in contrast with the placebo group. The five most abundant OTUs of the whole flora were *Faecalibacterium, Megamonas, Prevotella, Escherichia/Shigella* and *Bacteroides*. The OTU difference between the two groups was compared, and it was revealed that 18 OTUs altered in a significant manner. The first five are displayed in [Table VIII](#tVIII-ol-0-0-9906){ref-type="table"}. The beneficial OTU *Lactobacillus* and *Clostridium*, and the symbiotic OTU *Enterobacteriaceae*, were significantly increased in the CB group, though decreased in the placebo group. *C. butyricum* administration resulted in minor effects on the diversity of gut flora. In regard the phylum level, the proportion of each phylum in CB group was marginally altered, while in the placebo group the proportion of *Firmicutes* decreased significantly. In reference to the genus level, the CB group indicated an advantageous trend toward increased beneficial bacteria, while the pathogenic bacteria were decreased; this difference was not significant. The placebo group indicated the opposite. The beneficial OTUs were significantly increased in the CB group (P\<0.05) and decreased in the placebo group (P\<0.05).

Discussion
==========

The present study was prospective, random, double blind and placebo comparative, providing an indication that *C. butyricum* administration was a safe and effective treatment for chemotherapy-induced diarrhea in patients with lung cancer. *C. butyricum* maintained gut homeostasis and alleviated inflammatory response. However, no clear effects were obtained regarding immunity or nutrition.

Probiotics have been used in numerous types of gastrointestinal diseases, due to their ability to preserve the stability of the intestinal microenvironment. *C. butyricum* is a spore-like micro-ecological preparation. It was selected primarily for its notable tolerance to the gastric environment and temperature. *C. butyricum* produces butyric acid, the preferred energy source for intestinal epithelial cells, and promotes the proliferation of *Bifidobacteria* and *Lactobacilli* ([@b24-ol-0-0-9906]). It is also able to regulate gut homeostasis and alleviate the inflammatory response in IBD ([@b15-ol-0-0-9906]). Therefore, it was speculated that a potential beneficial effect against chemotherapy-induced diarrhea may be associated with numerous factors, including intestinal epithelial apoptosis, intestinal barrier dysfunction, intestinal flora structural changes and proinflammatory cytokine production ([@b12-ol-0-0-9906]). The results revealed that *C. butyricum* administration to patients with lung cancer reduced the incidence of chemotherapy-induced diarrhea. This result was similar to those obtained in earlier studies ([@b25-ol-0-0-9906]--[@b28-ol-0-0-9906]). The basis for this may involve intestinal epithelial cell repair promotion, intestinal homeostasis maintenance and intestinal inflammation reduction ([@b29-ol-0-0-9906]).

The diversity of the intestinal microflora ensures the stability of the intestinal microecology ([@b30-ol-0-0-9906]). Chemotherapy usually leads to reduced diversity of the intestinal flora ([@b31-ol-0-0-9906],[@b32-ol-0-0-9906]); a previous study highlighted a marked increase in *Bacteroides* and *Escherichia* following chemotherapy and a corresponding decrease in *Blautia, Faecalibacterium* and *Roseburia* at the genus level ([@b33-ol-0-0-9906]). In the present study, the diversity of the gut flora in the CB group did not decrease following chemotherapy, and the proportion of each phylum altered slightly, while in the placebo group, the proportion of *Firmicutes* decreased significantly. These results suggested that *C. butyricum* maintained the stability of the intestinal microflora. Furthermore, levels of such pathogenic bacteria as *Bacteroides* and *Escherichia* were decreased in the CB group, while beneficial bacteria, including *Blautia, Faecalibacterium* and *Roseburia* increased in number. These results may suggest that *C. butyricum* aided in the maintenance of gut homeostasis, and may also be responsible for the lower incidence of chemotherapy-induced diarrhea in the CB group.

Short-chain fatty acids (SCFAs) are considered to have beneficial effects, including nourishing intestinal epithelial cells and energy components to protect the intestinal mucosal barrier, reducing the level of inflammation and enhancing gastrointestinal motility ([@b34-ol-0-0-9906]). A previous study ([@b35-ol-0-0-9906]) revealed that SCFA-producing genera including *Phascolarctobacterium, Roseburia, Blautia, Faecalibacterium, Clostridium, Subdoligranulum, Ruminococcus, Coprococcus* and *Bacteroides* form the bulk of the gut flora to maintain human health; *C. butyricum* produces butyric acid, an SCFA, in the intestine. In the present study it was established that the majority of these genera were elevated in the CB group, suggesting that *C. butyricum* may promote the growth of SCFA-producing gut flora, thus facilitating intestinal mucosal repair and decreasing the incidence of diarrhea.

Cancer has been described as the 'wound that does not heal' ([@b36-ol-0-0-9906]). Thus, cancer is a course of persistent wounding and healing, with characteristic inflammation. Cells of the myeloid and lymphoid lineage have different effects on cancer progression and metastasis ([@b37-ol-0-0-9906]--[@b39-ol-0-0-9906]). Neutrophil degranulation of chemically toxic products and growth factors may have important effects on cancer progression, angiogenesis and invasion ([@b40-ol-0-0-9906]--[@b43-ol-0-0-9906]). Peripheral monocytes are recruited in tumor tissue by various chemokines ([@b44-ol-0-0-9906]). They may not only stimulate angiogenesis and enhance tumor cell invasion, but also prevent anti-tumor immunoreaction by natural killer and T cells during tumor progression and following chemotherapy ([@b45-ol-0-0-9906],[@b46-ol-0-0-9906]). Platelets secrete cytokines and growth factors which may contribute to cancer progression by influencing angiogenesis, cell migration, proliferation and epithelial to mesenchymal cell transition ([@b47-ol-0-0-9906]--[@b49-ol-0-0-9906]). Furthermore, lymphocytes serve a critical role in tumor defense by inducing cytotoxic cell death, and may suppress tumor cell proliferation and invasion ([@b50-ol-0-0-9906],[@b51-ol-0-0-9906]). The results of the present study have demonstrated that neutrophils, monocytes and platelets serve important roles in promoting inflammation and cancer, while lymphocytes may suppress tumor formation. Therefore, the ratio of the number of neutrophils, monocytes and platelets to the number of lymphocytes, (i.e. SIR biomarkers, including NLR, PLR and LMR) may serve as a reference for the degree of systemic inflammation in patients with cancer. Previous studies ([@b52-ol-0-0-9906]--[@b54-ol-0-0-9906]) illustrated that SIR biomarkers are associated with the progression and prognosis of lung cancer; increased NLR and PLR, and decreased LMR are associated with poor prognosis in lung cancer. The present study indicated that SIR biomarkers were significantly increased in the CB group compared with the placebo group, suggesting that *C. butyricum* effectively reduced the systemic inflammatory response.

It was hypothesized that *C. butyricum* may initially act by reducing intestinal inflammation. Within 3 weeks of administration *C. butyricum* may reduce the inflammatory response without causing notable variations in the intestinal flora. Increased incubation times or doses may have altered the composition of the gut flora, although this speculation requires further investigation.

Fluctuations in immune function and nutritional status were also investigated following administration of *C. butyricum*. Other studies have demonstrated that probiotics may inhibit the proliferation and growth of tumor cells ([@b55-ol-0-0-9906],[@b56-ol-0-0-9906]), which may be associated with enhanced immunity. Probiotics interact with intestinal epithelial cells through a variety of pattern recognition receptors, affecting cellular immune function and the inflammatory response ([@b57-ol-0-0-9906]--[@b61-ol-0-0-9906]). They are also able to stimulate the humoral immune response and increase IgG and IgA levels in a number of diseases ([@b62-ol-0-0-9906]--[@b65-ol-0-0-9906]). Few studies are available regarding probiotics and cellular immune function in patients with cancer. Zhang *et al* ([@b66-ol-0-0-9906]) performed a study on the effects of *C. butyricum* and *Bifidobacterium* on lymphocyte differentiation in late preterm infants, which revealed increased CD4^+^ and decreased CD8^+^ T cell numbers in the probiotic group compared with the control group (treated with simple formula milk); although the proportions of NK and B were not significantly different between the two groups. By contrast, the present study suggested an increased number of CD8^+^ T cells and NK cells, and a decreased number of CD4^+^ T cells in the CB group, although no significant difference was observed, suggesting that *C. butyricum* may promote the proliferation of CD8^+^ T cells and NK cells, to a cytotoxic end. It was speculated that these effects may be beneficial in patients with lung cancer. Further studies have illustrated that probiotics increase the concentration of IgG and IgA in patients with colorectal cancer, following surgery ([@b67-ol-0-0-9906],[@b68-ol-0-0-9906]). The present study illustrated that the concentration of all Igs decreased in the two groups, and the alterations were not statistically different. Therefore, it was supposed that *C. butyricum* administration for 3 weeks may not have a significant effect on the humoral immune response of patients undergoing chemotherapy.

Due to the rapid proliferation and consumption of nutrients by cancer cells, patients with malignant tumors are prone to malnutrition and cachexia. Albumin is the most abundant protein in serum and, to a certain extent, reflects the nutritional status of patients. Studies have demonstrated that supplementation with probiotics may improve the nutritional status of mice, increase serum albumin and maintain weight ([@b25-ol-0-0-9906],[@b69-ol-0-0-9906]). The present study did not reveal a significant difference in serum albumin or weight in the CB group, although in placebo group, there was a decrease in albumin and weight. These results indicated that *C. butyricum* administration for 3 weeks may not significantly impact the nutritional status of patients with cancer.

The present study had the following limitations: i) The number of participants was small, and the participants were not from multiple centers; ii) the intervention dose and time may be insufficient, thus specific indicators including immune function, nutritional status and fluctuations in flora genus did not significantly alter; and iii) due to the complex interplay between the intestinal flora and the human body, the study did not exclude confounding factors, including diet and drugs.

In conclusion, the present study indicated that supplementation with the probiotic *C. butyricum* in patients with lung cancer is safe. It decreased chemotherapy-induced diarrhea, reduced the systemic inflammatory response, and helped to maintain the condition of the intestinal flora. However, *C. butyricum* also weakly influenced the immune and nutrition status of patients. Despite this, the present results provided important evidence for probiotic supplementation during chemotherapy.
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![Flow chart of study. Patients with lung cancer were randomly divided at a 1:1 ratio to receive CB or the placebo treatment. Blood and stool specimens were collected at baseline. From the baseline onward, CB or the placebo was administered at a dose of three tablets/day, three times per day, for a total of 3 weeks. After 3 weeks, blood and stool samples were collected again. CB, *Clostridium butyricum*.](ol-17-03-2836-g00){#f1-ol-0-0-9906}

![Peripheral blood routine and systemic inflammatory response indicators. (A) Significant differences were identified in LYM between the two groups. NLR decreased significantly in the CB group. At week 3, LMR was significantly higher in the CB group compared the placebo group. (B) PLR decreased significantly in the CB group. (C) The changes of LYM between two groups demonstated significant difference. (D) The changes of PLR between two groups demonstrated significant difference. NEU, neutrophil; LYM, lymphocyte; MON, monocyte; PLT, platelet; NLR, neutrophil lymphocyte ratio; PLR, platelet/lymphocyte ratio; LMR, lymphocyte/monocyte ratio; CB, *Clostridium butyricum*. \*P\<0.05.](ol-17-03-2836-g01){#f2-ol-0-0-9906}

![Rarefaction curve. Curves tended to plateau as the number of sequencing events increased, suggesting that the samples were completely sequenced. OTU, operational taxonomy unit.](ol-17-03-2836-g02){#f3-ol-0-0-9906}

![Diversity indexes. (A) Shannon and (B) Chao indexes. The differences between groups and time points were compared, and no significant differences were indicated. The change between groups was also not significantly different. CB, *Clostridium butyricum*.](ol-17-03-2836-g03){#f4-ol-0-0-9906}

![PCoA analysis. PCoA analysis on OTU levels at (A) baseline and (B) week 3. PC1 and PC2 indicates the two most important factors impacting the grouping. No significant impact was identified to the grouping at the two time points. T1: CB group at baseline; T2: CB group at week 3. C1: placebo group at baseline; C2: placebo group at week 3. CB, *Clostridium butyricum*; PCoA, principal coordinates analysis; OTU, operational taxonomy unit. PC, principal coordinates; C, control; T, treatment.](ol-17-03-2836-g04){#f5-ol-0-0-9906}

![Differences in phylum level in the (A) CB and (B) placebo groups at two time points. Four primary phyla were identified. The proportion of phyla altered in the CB group, while the proportion of *Firmicutes* decreased significantly in the placebo group. CB, *Clostridium butyricum;* C, control; T, treatment.](ol-17-03-2836-g05){#f6-ol-0-0-9906}

![Genus differences in the CB and placebo groups. No significant difference was observed in either group. However, the most beneficial genera including *Faecalibacterium, Lactobacillus, Clostridum, Blautia* and *Roseburia* were elevated in number. The pathogenic bacteria *Escherichia/Shigella* decreased in the CB group, and increased in the placebo group. CB, *Clostridium butyricum*.](ol-17-03-2836-g06){#f7-ol-0-0-9906}

###### 

Patient characteristics of the CB and placebo groups.

  Characteristic   CB group   Placebo group   P-value
  ---------------- ---------- --------------- ---------
  Sex                                         
    Male           15         15              0.837
    Female         5          6               
  Age, years       57±8.75    54±8.35         0.196
  Cancer stage                                
    I              0          0               0.986
    II             3          3               
    III            8          8               
    IV             9          10              

Results are expressed as the median ± standard deviation. Statistical significance was determined by Wilcoxon test. CB, *Clostridium butyricum*.

###### 

Variations in weight and ALB of the CB and placebo groups.

                                Time point                            
  ------------- --------------- ------------- -------------- -------- --------
  ALB (g/l)     CB              38.28±3.928   39.135±4.611   0.4987   0.1589
                Placebo         38.49±4.767   37.32±5.047    0.3519   
                P-inter value   0.4414        0.3751         --       
  Weight (kg)   CB              65.5±9.13     65.47±8.55     0.9460   0.501
                Placebo         64.5±11.67    63.78±11.80    0.7626   
                P-inter value   0.5925        0.4810         --       

Results are expressed as the median ± standard deviation. The P-intra value indicates the P-value between two time points within the same group, calculated by Wilcoxon test. The P-inter value indicates the P-value between the two groups at the same time point, calculated by Wilcoxon test. P-values were obtained with the comparison of the changes of two groups calculated using the Wilcoxon test. ALB, albumin level; CB, *Clostridium butyricum*.

###### 

Incidence of chemotherapy inducing nausea, vomiting and diarrhea, in the CB and placebo groups.

              Group                    
  ----------- ---------- ------------- -------
  Nausea                               
    Grade 1   12 (60%)   8 (38.10%)    0.166
    Grade 2   8 (40%)    13 (61.90%)   
    Grade 3   0          0             
  Vomiting                             
    Grade 1   3 (15%)    2 (9.52%)     0.254
    Grade 2   15 (75%)   14 (66.67%)   
    Grade 3   2 (10%)    5 (23.81%)    
    Grade 4   0          0             
    Grade 5   0          0             
  Diarrhea                             
    Absent    15 (75%)   8 (38.09%)    0.017
    Grade 1   4 (20%)    9 (42.86%)    
    Grade 2   1 (5%)     3 (14.29%)    
    Grade 3   0          1             
    Grade 4   0          0             
    Grade 5   0          0             

Adverse effects were graded according to the Criteria for Adverse Events. The grade of nausea was divided into three levels. The grades of vomiting and diarrhea were divided into five levels. The incidences between two groups were compared by Wilcoxon test. CB, *Clostridium butyricum*.

###### 

Percentages of lymphocyte subsets in the CB and placebo groups.

                                        Time point                             
  --------------------- --------------- -------------- -------------- -------- --------
  T lymphocyte          CB              69.62±10.27    69.94±11.25    0.9246   0.8136
  CD3^+^                Placebo         70.07±6.825    71.20±9.492    0.5886   
                        P-inter value   0.5919         0.7052         --       
  CD4^+^ T lymphocyte   CB              42.19±8.329    39.10±6.848    0.3147   0.4984
  CD3^+^CD4^+^          Placebo         39.54±10.13    41.05±9.565    0.8264   
                        P-inter value   0.4053         0.8923                  
  CD8^+^ T lymphocyte   CB              25.87±8.74     26.81±8.40     0.7306   0.9622
  CD3^+^CD8^+^          Placebo         27.13±8.33     27.62±9.82     0.9281   
                        P-inter value   0.6486         0.7991         --       
  CD4^+^/CD8^+^ ratio   CB              1.829±0.6937   1.629±0.5387   0.4956   0.6931
                        Placebo         1.687±0.8696   1.757±0.8488   0.8347   
                        P-inter value   0.5734         0.5987         --       
  Natural killer cell   CB              17.70±8.739    19.41±11.99    0.4248   0.4402
  CD16^+^CD56^+^        Placebo         16.97±7.214    17.27±7.663    0.8813   
                        P-inter value   0.7888         0.4262         --       
  B lymphocyte          CB              11.48±3.689    9.231±2.929    0.0706   0.9875
  CD19^+^               Placebo         11.94±5.349    10.66±5.858    0.4007   
                        P-inter value   0.7888         0.5567         --       

Results are expressed as the mean ± standard deviation. P-intra values indicate the P-values between two time points within the same group calculated by Wilcoxon test. P-inter values indicate the P-value between the two groups at the same time point, calculated by Wilcoxon test. P-values were obtained via the comparison of the changes of two groups calculated using the Wilcoxon test. CB, *Clostridium butyricum;* CD, cluster of differentiation.

###### 

Serum Ig concentrations in the CB and placebo groups.

                                Time points                            
  ------------- --------------- -------------- -------------- -------- --------
  IgG (g/l)     CB              12.44±2.584    11.61±1.767    0.1727   0.4274
                Placebo         10.82±2.769    10.52±2.232    0.7459   
                P-inter value   0.05789        0.1207         --       
  IgA (g/l)     CB              2.341±0.8865   2.169±0.7771   0.4099   0.5928
                Placebo         2.316±0.8892   2.189±0.6528   0.7781   
                P-inter value   0.9568         0.7917         --       
  IgM (g/l)     CB              1.151±0.3478   1.131±0.3060   0.9584   0.8147
                Placebo         1.087±0.4358   1.012±0.3830   0.8436   
                P-inter value   0.9451         0.8734         --       
  IgE (IU/ml)   CB              206.5±343.0    84.98±87.45    0.4527   0.7162
                Placebo         133.5±186.2    99.71±156.2    0.8436   
                P-inter value   0.4634         0.4753         --       

Results are expressed as the mean ± standard deviation. P-intra values indicate the P-values between two time points within the same group calculated by Wilcoxon test. P-inter values indicate the P-value between the two groups at the same time point, calculated by Wilcoxon test. P-values were obtained via the comparison of the changes of two groups calculated using the Wilcoxon test. CB, *Clostridium butyricum;* Ig, immunoglobulin.

###### 

ANOSIM analysis between the two groups of the operational taxonomy unit level at baseline and week 3.

  ANOSIM     Statistic   P-value   Permutation number
  ---------- ----------- --------- --------------------
  Baseline   −0.0154     0.69      999
  Week 3     −0.0315     0.905     999

ASOSIM, analysis of similarity.

###### 

Adonis analysis between the two groups of the operational taxonomy level at baseline and week 3.

  Time point   ADONIS            Df    Sums of Sqs   Mean Sqs   F.Model   R^2^      Pr(\>F)
  ------------ ----------------- ----- ------------- ---------- --------- --------- ---------
  Baseline     Group_factor\$G     1     0.2563      0.25630    0.73394   0.01847   0.796
               Residuals         39    13.6191       0.34921    0.98153             
               Total             40    13.8754       1.00000                        
  Week 3       Group_factor\$G     1     0.1901      0.19006    0.61786   0.0156    0.963
               Residuals         39    11.9971       0.30762    0.9844              
               Total             40    12.1872       1.00000                        

Group_factor\$G, grouping scheme; Df, degree of freedom; SumsOfSqs, total variance; MeanSqs, mean square (difference); F.Model, F test value; R^2^, reflects grouping differences, the higher the value, the higher the grouping differences; Pr, P-value \>0.05 indicating the high degree of reliability of this test.

###### 

The five most significant altered OTUs between the two groups.

                       OTU (%)                                                                                                   
  --------- ---------- ------------------------ ------------------------ --------------------------- --------------------------- ----------------------
  CB        Baseline   0.0009718±0.003765       4.485×10^−5^±0.0001048   0                           1.75×10^−6^±7.823×10^−6^    0.0005069±0.0005698
            Week 3     0.005521±0.01891         0.01100±0.04799          0.001646±0.003456           0.0004368±0.0009479         0.0001587±0.0002634
  Placebo   Baseline   5.381×10^−6^±0.09040     0.001212±0.004044        5.38×10^−6^±1.881×10^−5^    0.001057±0.003162           0.0004179±0.001048
            Week 3     6.290×10^−6^±0.0001563   0.0004852±0.001259       8.714×10^−6^±3.426×10^−5^   1.952×10^−5^±4.595×10^−5^   0.0001256± 0.0002203

Results are expressed as the mean ± standard deviation. P-values were calculated by Kruskal-Wallis test. Numbers 1 and 2 represent the two time points, baseline and week 3, respectively. OTU, operational taxonomy unit; CB, *Clostridium butyricum*.
